Phase-3 trials find 1-shot chikungunya vaccine safe: Lancet

The first chikungunya vaccine may be on its way with phase 3 trials of a single-shot jab developed by French biotech company Valneva showing the vaccine to be generally safe, well tolerated and provoking an immune response. The study was conducted in the US. Its success will have significant implications for nations like India where chikungunya is endemic.

from Times of India https://ift.tt/GYK06pP
https://ift.tt/1sEtmXj June 13, 2023 at 12:59AM DURGESH NANDAN JHA

Comments

Popular posts from this blog

Covid live: Record 50,000+ infections on Sunday

Impact of pandemic? Women jobseekers fell by 34% in 2021

SC slams trial courts for seeking needless custody